HIV sequence databases

AIDS Reviews

Volumn 5, Issue 1, 2003, Pages 52-61

  Kuiken, Carla ^a   Korber, Bette ^a   Shafer, Robert W ^b  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analysis; Database; Evolution; Genetic sequences; HIV; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; DNA; ENFUVIRTIDE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE;

CLINICAL TRIAL; DATA ANALYSIS; DATA BASE; DRUG SCREENING; GENE SEQUENCE; GENETIC CORRELATION; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNET; LYMPHOCYTE COUNT; MEDICAL RESEARCH; MEXICO; NONHUMAN; PHENOTYPE; REVIEW; SEQUENCE ANALYSIS; UNITED STATES; VIRUS GENE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; DATABASES, GENETIC; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS;

EID: 0037622956     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Robertson D, Gao F, Hahn HB, Sharp P. Intersubtype recombinant HIV-1 sequences. In: Korber B, Hahn B, Foley B, et al. (eds). Human Retroviruses and AIDS 1997. Los Alamos: Los Alamos National Laboratory 1997.
2. Kuiken C, Korber B. Sequence quality control. In: Korber B, Kuiken CL, Foley B, et al. (eds). Human Retroviruses and AIDS 1998. Los Alamos: Los Alamos National Laboratory 1998.
3. Siepel A, Halpern A, Macken C, Korber B. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res Hum Retroviruses 1995;11:1413-6.
4. Korber B, Foley B, Kuiken C, Pillai S, Sodroski J. Numbering positions in HIV relative to HXB2CG. In: Korber B, Kuiken C, Foley B, et al. (eds). Human Retroviruses and AIDS. Los Alamos: Los Alamos National Laboratory 1998.
5. Robertson D, Bradac J, Foley B, et al. HIV-1 nomenclature proposal. Science 2000;5463.
6. Parikh U, Hammond J, Calef C, Larder B, Schinazi R, Mellors J. Mutations in retroviral genes associated with drug resistance. In: Kuiken C, Foley B, Hahn B, et al. (eds). HIV Sequence Compendium. Los Alamos, NM: Los Alamos National Laboratory 2001.
7. Cormier E, Dragic T. An overview of HIV-1 coreceptor function and its inhibitors. In: Kuiken C, Foley B, Hahn B, et al. (eds). HIV Sequence Compendium. Los Alamos, NM: Los Alamos National Laboratory 2000.
8. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-60.
9. Warren J, Levinson M. Fourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. J Med Primatol 1995;24:150-68.
10. Sharp P, Bailes E, Robertson D, Gao F, Hahn B. Origins and evolution of AIDS viruses. Biol Bull 1999;196:338-42.
11. Hahn B, Shaw G, De Cock K, Sharp P. AIDS as a zoonosis: Scientific and public health implications. Science 2000;287:607-14.
12. Chen Z, Luckay A, Sodora D, et al. HIV-2 seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J Virol 1997;71:3953-60.
13. Gao F, Robertson D, Morrison S, et al. The heterosexual HIV type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996;70:7013-29.
14. Carr J, Salminen M, Koch C, et al. Full-length sequence and mosaic structure of a HIV type 1 isolated from Thailand. J Virol 1996;70:5935-43.
15. Gaschen B, Kuiken C, Korber B, Foley B. Retrieval and on-the-fly alignment of sequence fragments from the HIV database. Bioinformatics 2001;17:415-8.
16. Yang Z, Nielsen R, Hasegawa M. Models of amino acid substitution and applications to mitochondrial protein evolution. Mol Biol Evol 1998;15:1600-11.
17. Rose P, Korber B. Detecting hypermutations in viral sequences with an emphasis on G → A hypermutation. Bioinformatics 2000;16:400-1.
18. Calef C. Numbering positions in SIV relative to SIVMM239. In: Kuiken C, Foley B, Hahn B, et al. (eds). Human Retroviruses and AIDS. Los Alamos: Los Alamos National Laboratory 2001.
19. Higgins D. Sequence ordinations: A multivariate analysis approach to analysing large sequence data sets. Comput Appl Biosci 1992;8:15-22.
20. Delwart E, Gordon C. Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods 1997;12:348-54.
21. Hirsch M, Brun-Vezinet F, D'Aquila R, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA 2000;283:2417-26.
22. Demeter L, Haubrich R. Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations. J Acquir Immune Defic Syndr 2001;26(Suppl 1):3-9.
23. Haubrich R, Demeter L. Clinical utility of resistance testing: Retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr 2001;26(Suppl 1):51-9.
24. Miller V, Larder B. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 2001;6(Suppl 3):25-44.
25. Miller V. Resistance to protease inhibitors. J Acquir Immune Defic Syndr 2001;26(Suppl 1):34-50.
26. Hanna G, D'Aquila R. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001;32:774-82.
27. Shafer R. Genotypic testing for HIV type 1 drug resistance. Clin Microbiol Rev 2002;15:247-77.
28. Kantor R, Machekano R, Gonzales M, Dupnik B, Schapiro J, Shafer R. HIV reverse transcriptase and protease sequence database: An expanded model integrating natural language text and sequence analysis. Nucleic Acids Res 2001;29:296-9.
29. Gonzales M, Dugan J, Shafer R. Synonymous-non-synonymous mutation rates between sequences containing amibiguous nucleotides (Syn-SCAN). Bioinformatics 2002;18:886-7.
30. Shafer R, Jung D, Betts B. HIV type 1 reverse transcriptase and protease mutation search engine for queries. Nat Med 2000;6:1290-2.
31. Kilby J, Hopkins S, Venetta T, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4:1302-7.
32. Clotet B, Lazzarin A, Cooper D, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals in Europe and Australia. World AIDS Conference. Barcelona 2002 [LbOr19A].
33. Henry K, Lalezari J, O'Hearn M, et al. Enfuvirdie (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three drug classes of approved antiretrovirals in North America and Brazil. World AIDS Conference. Barcelona 2002 [LbOr19B].
34. Kantor R, Katzenstein D, Gonzales M, et al. Influence of subtype and treatment on genetic profiles for HIV-1 reverse transcriptase and protease: Do they act independently in predicting mutation specific probabilities in non-subtype B sequences. Antivir Ther 2002;7(Suppl):142.
35. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001;322:1087-8.
36. Simon V, Vanderhoeven J, Hurley A, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002;16:1511-9.
37. Grant R, Hecht F, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-8.
38. Little S, Holte S, Routy J, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94.
39. Gonzales MJ, Machekano R, Shafer R. HIV type 1 reverse transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis 2001;184:998-1006.
40. Schiffer C, Scott W, Stewart F, King M, Kempf D. The uncommon HIV-1 protease mutation I54T is highly associated with G48V and may affect cleavage dynamics by stabilizing the structure of the flaps. Antivir Ther 2001;6(Suppl 1):52.
41. Winters M, Merigan T. Variants other than aspartic acid at codon 69 of the HIV type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs. Antimicrob Agents Chemother 2001;45:2276-9.